Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary Central Nervous System Lymphoma

Primary central nervous system lymphoma (PCNSL) harbors mutations that reinforce B cell receptor (BCR) signaling. Ibrutinib, a BTK inhibitor, targets BCR signaling and is particularly active in lymphomas with BCR and MYD88 mutations. We performed a proof of concept phase Ib study of ibrutinib monoth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Lionakis, Michail S., Dunleavy, Kieron, Roschewski, Mark, Widemann, Brigitte C., Butman, John A., Schmitz, Roland, Cole, Diane E., Melani, Christopher, Higham, Christine S., Desai, Jigar V., Ceribelli, Michele, Chen, Lu, Thomas, Craig J., Little, Richard F., Gea-Banacloche, Juan, Bhaumik, Sucharita, Stetler-Stevenson, Maryalice, Pittaluga, Stefania, Jaffe, Elaine S., Heiss, John, Lucas, Nicole, Steinberg, Seth M., Staudt, Louis M., Wilson, Wyndham H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5571650/
https://ncbi.nlm.nih.gov/pubmed/28552327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2017.04.012
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados